Literature DB >> 16916343

Trastuzumab (Herceptin)-associated lung injury.

Bobbak Vahid1, Anita Mehrotra.   

Abstract

We report a case of trastuzumab pneumonitis in a patient with metastatic breast cancer. Bronchoalveolar lavage showed marked neutrophilia. A CT scan of the chest showed diffuse ground-glass opacities. The patient was treated with corticosteroids with a partial response. Trastuzumab-associated pneumonitis is not well described, and data in the literature is sparse. We describe the clinical and radiographical findings of trastuzumab-associated pneumonitis.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16916343     DOI： 10.1111/j.1440-1843.2006.00907.x

Source DB:  PubMed          Journal:  Respirology        ISSN： 1323-7799            Impact factor:   6.424


  13 in total

1.  An unusual flare of anti-synthetase syndrome during concurrent trastuzumab therapy given for recurrent breast cancer.

Authors:  Timothy D Reynolds; Vivek Mohan; Matthew Roy; Nathan Manghat; Huzaifa Adamali; Harsha Gunawardena
Journal:  Eur J Rheumatol       Date:  2017-10-25

2.  Interstitial lung disease associated with trastuzumab monotherapy: A report of 3 cases.

Authors:  Akinori Sugaya; Shingo Ishiguro; Shoichi Mitsuhashi; Masahiro Abe; Ikuta Hashimoto; Takayuki Kaburagi; Hiroshi Kojima
Journal:  Mol Clin Oncol       Date:  2016-12-19

3.  Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831.

Authors:  Michele Y Halyard; Thomas M Pisansky; Amylou C Dueck; Vera Suman; Lori Pierce; Larry Solin; Larry Marks; Nancy Davidson; Silvana Martino; Peter Kaufman; Leila Kutteh; Shaker R Dakhil; Edith A Perez
Journal:  J Clin Oncol       Date:  2009-04-06       Impact factor: 44.544

Review 4.  Anticancer therapy and lung injury: molecular mechanisms.

Authors:  Li Li; Henry Mok; Pavan Jhaveri; Mark D Bonnen; Andrew G Sikora; N Tony Eissa; Ritsuko U Komaki; Yohannes T Ghebre
Journal:  Expert Rev Anticancer Ther       Date:  2018-07-23       Impact factor: 4.512

5.  Delayed Paclitaxel-trastuzumab-induced interstitial pneumonitis in breast cancer.

Authors:  Omalkhair Abulkhair; Wael El Melouk
Journal:  Case Rep Oncol       Date:  2011-04-02

Review 6.  Adverse events of monoclonal antibodies used for cancer therapy.

Authors:  Mei Guan; Yan-Ping Zhou; Jin-Lu Sun; Shu-Chang Chen
Journal:  Biomed Res Int       Date:  2015-05-05       Impact factor: 3.411

Review 7.  New targeted molecular therapies for cancer: radiological response in intrathoracic malignancies and cardiopulmonary toxicity: what the radiologist needs to know.

Authors:  Frederico F Souza; Andrew Smith; Cyrillo Araujo; Jyothi Jagannathan; Ciaran Johnston; Kevin O'Regan; Atul Shinagare; Nikhil Ramaiya
Journal:  Cancer Imaging       Date:  2014-07-23       Impact factor: 3.909

8.  Trastuzumab tolerability in the treatment of advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress HER2/neu.

Authors:  Joan Tymon-Rosario; Eric R Siegel; Stefania Bellone; Justin Harold; Naomi Adjei; Burak Zeybek; Dennis Mauricio; Gary Altwerger; Gulden Menderes; Elena Ratner; Mitchell Clark; Vaagn Andikyan; Gloria S Huang; Masoud Azodi; Peter E Schwartz; Amanda N Fader; Alessandro D Santin
Journal:  Gynecol Oncol       Date:  2021-08-06       Impact factor: 5.304

9.  Neglected respiratory toxicity caused by cancer therapy.

Authors:  Christian Domingo; Jorge Roig
Journal:  Open Respir Med J       Date:  2007-07-30

10.  Metronomic chemotherapy in the neoadjuvant setting: results of two parallel feasibility trials (TraQme and TAME) in patients with HER2+ and HER2- locally advanced breast cancer.

Authors:  V Petry; D M Gagliato; A I C Leal; R J Arai; E Longo; F Andrade; M D Ricci; J R Piato; R Barroso-Sousa; P M Hoff; M S Mano
Journal:  Braz J Med Biol Res       Date:  2015-03-06       Impact factor: 2.590
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.